Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant, Human PD-1 / PDCD1 Protein, Strep Tag, 25µg  

Recombinant, Human PD-1 / PDCD1 Protein, Strep Tag, 25µg

Recombinant Human PD-1 /PDCD1 Protein, With C-Twin Strep Tag (rh PD1/PDCD1,twin strep tag) Leu 25 - Gln 167 was produced in human 293 cells (HEK293).

Synonym: recombinant, human, protein, PDCD1, PD1, CD279, SLEB2

More details

PD1-H5284-025

Availability: within 7 days

312,00 €

Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Source
Recombinant Human PD-1, Strep Tag (PD1-H5284) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
N-terminal Sequence Analysis: Leu 25

Molecular Characterization
This protein carries a twin strep tag at the C-terminus.
The protein has a calculated MW of 19.0 kDa. The protein migrates as 30-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rh PD1/PDCD1,twin strep tag by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors"
Martorana, Colombo, Treglia et al
Cancer Treat Rev (2021) 101, 102300
(2) "FDG-PET to predict long-term outcome from anti-PD1 therapy in metastatic melanoma"
Dimitriou, Lo, Tan et al
Ann Oncol (2021)
(3) "Rapid detoxification of Microcystin-LR by selective catalytic hydrogenation of the Adda moiety using TiO2-supported Pd catalysts"
Sun, Liu, Alvarez et al
Chemosphere (2021)
Showing 1-3 of 19840 papers.